Vanda Pharmaceuticals' GAAP loss for 3 months of 2022 was $6.43 million, compared to a profit of $8.65 million in the previous year. Revenues decreased by 4% to $60.192 mln against $62.669 mln in the previous year.

Net income of Vanda Pharmaceuticals under GAAP for 2021 was $33.152 million, up 42.1% from $23.337 million in the previous year. Revenue increased 8.3% to $268.682 million from $248.168 million a year earlier.

Vanda Pharmaceuticals' GAAP net profit for 9M 2021 was $26.074 mln, up 72.1% compared to $15.147 mln in the previous year. Revenue increased 11.2% to $200.663 million from $180.515 million a year earlier.

The net profit of Vanda Pharmaceuticals according to GAAP for 6 months of 2021 amounted to $18.303 mln, having doubled as compared to $9.2 mln in the previous year. Revenue increased 8.6% to $130.568 million from $120.207 million a year earlier.